Regulatory Teva Receives FDA Approval of Denosumab Biosimilar and Filing Acceptances by FDA and EMA For Omalizumab Biosimilar Big Molecule WatchOn March 30, 2026, Teva Pharmaceutical Industries Ltd.RegulatoryRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) Big Molecule Watch On March 30, 2026, Teva Pharmaceutical Industries Ltd. RegulatoryRead full story Post navigation Previous: Lilly launches GLP-1 pill, kicking off showdown with Novo NordiskNext: Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
